Functional pain syndromes, such as fibromyalgia and temporomandibular disorder, are associated with enhanced catecholamine tone and decreased levels of catechol-O-methyltransferase (COMT; an enzyme that metabolizes catecholamines). Consistent with clinical syndromes, our lab has shown that sustained 14-day delivery of the COMT inhibitor OR486 in rodents results in pain at multiple body sites and pain-related volitional behaviors. The onset of COMT-dependent functional pain is mediated by peripheral β 2 -and β 3 -adrenergic receptors (β 2 -and β 3 ARs) through the release of the pro-inflammatory cytokines tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Here, we first sought to investigate the role of β 2 -and β 3 ARs and downstream mediators in the maintenance of persistent functional pain. We then aimed to characterize the resulting persistent inflammation in neural tissues (neuroinflammation), characterized by activated glial cells and phosphorylation of the mitogen-activated protein kinases (MAPKs) p38 and extracellular signal-regulated kinase (ERK). Separate groups of rats were implanted with subcutaneous osmotic mini-pumps to deliver OR486 (15 mg/kg/day) or vehicle for 14 days. The β 2 AR antagonist ICI118551 and β 3 AR antagonist SR59230A were coadministrated subcutaneously with OR486 or vehicle either on day 0 or day 7. The TNFα inhibitor Etanercept, the p38 inhibitor SB203580, or the ERK inhibitor U0126 were delivered intrathecally following OR486 cessation on day 14. Behavioral responses, pro-inflammatory cytokine levels, glial cell activation, and MAPK phosphorylation were measured over the course of 35 days. Our results demonstrate that systemic delivery of OR486 leads to mechanical hypersensitivity that persists for at least 3 weeks after OR486 cessation. Corresponding increases in spinal TNFα, IL-1β, and IL-6 levels, microglia and astrocyte activation, and neuronal p38 and ERK phosphorylation were observed on days 14-35. Persistent functional pain was alleviated by systemic delivery of ICI118551 and SR59230A beginning on day 0, but not day 7, and by spinal delivery of Etanercept or SB203580 beginning on day 14. These results suggest that peripheral β 2 -and β 3 ARs drive persistent COMT-dependent functional pain via increased activation of immune cells and production of pro-inflammatory cytokines, which promote neuroinflammation and nociceptor activation. Thus, therapies that resolve neuroinflammation may prove useful in the management of functional pain syndromes.
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Introduction
Functional pain syndromes (FPS), including fibromyalgia (FM), temporomandibular disorder (TMD), tension-type headache (TTH), and irritable bowel syndrome (IBS), represent a significant healthcare problem that affect nearly one in every three Americans (Clauw, 2014; Dzau and Pizzo, 2014; Rey and Talley, 2009; Slade et al., 2013; Tsang et al., 2008; Wesselmann et al., 2014) . These conditions are characterized by persistent pain in the absence of tissue damage and often co-occur, thereby affecting multiple body sites. Accumulating evidence suggests that the origins of FPS are linked to abnormalities in catecholaminergic tone. Patients with FPS have increased levels of the catecholamines epinephrine and norepinephrine (Bote et al., 2014; Evaskus and Laskin, 1972; Perry et al., 1989; Torpy et al., 2000) https://doi.org/10.1016/j.bbi.2018.06.017 Received 20 November 2017; Received in revised form 11 June 2018; Accepted 20 June 2018
